Jefferies Reiterates Buy Rating on Veru, Inc. (VERU), Upside DCF PT $98
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Brookline Capital Markets Reiterates Buy Rating on Veru, Inc. (VERU), PT $31
July 6, 2022 4:30 PM EDTBrookline Capital Markets analyst Kumaraguru Raja reiterated a Buy rating and $31.00 price target on Veru, Inc. (NASDAQ: VERU)
The analyst comments "Results of the Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin, for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute... More
Veru, Inc. (VERU) Adds to Earlier Gain, Up 17% Afterhours
July 6, 2022 4:21 PM EDTVeru, Inc. (NASDAQ: VERU) Adds to Earlier Gain, Up 17% Afterhours
Veru, Inc. (VERU) Extends Gain, Now Up 20%
July 6, 2022 9:54 AM EDTVeru, Inc. (NASDAQ: VERU) Extends Gain, Now Up 20%
... MoreVeru (VERU) Climbs 7% After Publication of Phase 3 Data on Sabizabulin
July 6, 2022 7:33 AM EDTVeru, Inc. (NASDAQ: VERU) Climbs 7% After Reporting Publication of Phase 3 Data Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
... MoreVeru, Inc. (VERU) Reports Publication of Phase 3 Data Demonstrating that Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized COVID-19 Patients
July 6, 2022 7:31 AM EDTVeru Inc. (NASDAQ: VERU) today announced the publication of the results from a Phase 3 COVID-19 study evaluating the efficacy and safety of oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death in The New England Journal of Medicine (NEJM)... More